BLR&D Research Career Scientist Award Application
BLR&D Research Career Scientist Award Application
批准号:
10618238
负责人:
Harikrishna Nakshatri
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-04-01 至 2025-03-31
关键词:
AddressAffectAfrican ancestryAnimal ModelAppearanceAtlasesAwardBiologicalBiological MarkersBiologyBladderBody Weight decreasedBook ChaptersBreastBreast Cancer ModelBreast Cancer PatientBreast Epithelial CellsBreast cancer metastasisCachexiaCancer PatientCancer SurvivorCellsCellular biologyCessation of lifeCharacteristicsChemopreventionChemoresistanceChronicClassificationClinicClinicalClinical TrialsCollaborationsColorectalCommunicationComplement Factor HCountryDefectDependenceDevelopmentDistantDrug usageEstrogen AntagonistsEstrogensEventExposure toExtramural ActivitiesFacultyFunctional disorderFundingFutureGeneticGenomicsGoalsGrant ReviewGrowthHead and Neck CancerHealthHealthcareHigh School FacultyHigh School StudentHormone ResponsiveHormonesHumanInflammationInfrastructureInstitutionInternationalJournalsKnowledgeLaboratoriesLicensingLifeLinkLungMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMammary Gland ParenchymaMapsMedical StudentsMentorsMethodsMicroRNAsMindModalityMolecularMuscleMuscle functionMuscular AtrophyNatureNeoplasm MetastasisOncogenesOrganOutcomeOxygenPI3 genePI3K/AKTPIK3CG genePancreasPathway interactionsPatientsPersonsPharmaceutical PreparationsPhenotypePhosphotransferasesPostdoctoral FellowPrevention strategyProcessProductivityProto-Oncogene Proteins c-aktPublicationsPublished CommentPublishingQuality of lifeReportingResearchResearch PersonnelResistanceResistance developmentResourcesRestReview CommitteeRiskRoleScientistScreening for cancerSeminalSex DifferencesSignal PathwaySkeletal MuscleSocioeconomic FactorsSystemic diseaseTechniquesTechnologyTestingTherapeuticTissue BanksTissuesToremifeneVeteransWomanWorkanticancer researchbiomarker discoverybonebreast cancer progressioncancer cellcancer initiationcancer stem cellcancer typecarcinogenesiscareerchemotherapyeditorialeffective therapyepithelial to mesenchymal transitionestrogenicexperiencefemale sex hormonegenomic aberrationsgenomic datagraduate studenthealth disparityhigh riskhormone therapyimprovedinhibitorlecturesmalignant breast neoplasmmembermenmuscle formnutritionpreventprogramsreceptorsexsingle cell sequencingskeletal muscle wastingstatisticsstem cellssummer researchsymptom managementtherapy developmenttherapy resistanttreatment effecttreatment responsetumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project summary:
My current research is focused on understanding mechanisms by which breast cancer initiates and
progresses. While many studies on breast cancer progression are focused on cancer cell biology, we are
evaluating breast cancer as a systemic disease that influences the function of multiple organs. Breast cancer-
associated deaths are not simply due to metastasis of cancer cells to distant organs or resistance to treatment
but also due to its deleterious effects of cancer on bone and skeletal muscle. Unlike lung and pancreatic
cancers where cancer leads to debilitating weight loss and clinical appearance of cachexia, physical
appearance of most breast cancer patients remains “normal”. However, loss of skeletal muscle mass without
overt loss of body weight is very common and this loss of muscle mass is associated with poor outcome. In our
VA funded study, we are molecularly dissecting cancer-associated skeletal muscle changes, developing
biomarkers of skeletal muscle changes for early detection of cancer-induced systemic effects, and therapeutic
modalities to limit the effects of cancer on skeletal muscle. These studies are extended to other cancers
including bladder, lung, pancreatic, and head and neck cancers. We observed specific molecular differences in
skeletal muscle of men and women with the same type of cancers. Thus, there are sex-dependent differences
in cancer progression pathways, which are being explored to develop therapies that may be applicable to men
with cancer. Since 11% of patients treated at VA are cancer survivors, our studies have important implications
in improving health care at VA.
Additional studies in the laboratory are on 1) mechanisms associated with breast cancer metastasis
and therapeutic resistance; 2) genetic ancestry-dependent variability in the normal breast biology; 3) defining
cell-of-origin of breast cancer using single cell genomics, 4) the impact of exposure to extraphysiologic oxygen
on normal and cancer stem cells; and 5) developing chemoprevention strategies by understanding earliest
events in breast cancer initiation. These studies have no overlap with VA-funded studies and funded by
independent agencies. Goals of these ongoing efforts are to comprehensively understand breast cancer
development and progression and to further contribute to individualizing breast cancer characterization and
treatment. We aim to develop methods to classify breast cancer based on cell-of-origin and explore therapeutic
modalities based on genomic aberrations. Our study on the effects of extraphysiologic oxygen is expected to
change the method of tissue collection for biomarker discovery. The laboratory has been very productive over
the years with 29 publications since 2015 including two recent co-author publications in prestigious journals
Nature and Nature Communications and several senior author publications in journals such as Cancer
Research. Our publications have received more than 15,100 citations with H-factor of 62. The institutional
infrastructure, both at IU and VA, and collaborations within and outside the institution and continuous
extramural funding for the past 23 years enabled us to achieve these goals.
In addition to research, I have been involved in mentoring junior faculty, post-doctoral fellows, graduate
students, medical students, high school students, and high school teacher summer research for the past 23
years (>50 mentees). I served/serve in various grant review committees at national and international levels and
serve as an editor of prestigious journals such as Cancer Research. Since 2015, I have given 37 invited
lectures at national and international venues highlighting the significance and recognition of our research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Summer Program for Academic Research in Cancer (SPARC)
-
批准号:10628221
-
项目类别:
-
资助金额:$29.58万
-
财政年份:2023
-
负责人:Harikrishna Nakshatri
-
依托单位:
BLR&D Research Career Scientist Award Application
-
批准号:10451507
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Harikrishna Nakshatri
-
依托单位:
Mechanisms associated with systemic effects of cancer
-
批准号:10515659
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Harikrishna Nakshatri
-
依托单位:
Mechanisms associated with systemic effects of cancer
-
批准号:10296651
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Harikrishna Nakshatri
-
依托单位:
Mechanisms associated with systemic effects of cancer
-
批准号:10043823
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:Harikrishna Nakshatri
-
依托单位:
Estrogen-Estrogen Receptor axis in non-transformed breast epithelial cells: studies beyond MCF-7
-
批准号:9024970
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2015
-
负责人:Harikrishna Nakshatri
-
依托单位:
Anthrax Toxin Receptor as a marker and target of breast cancer stem cells
-
批准号:8113776
-
项目类别:
-
资助金额:$20.1万
-
财政年份:2011
-
负责人:Harikrishna Nakshatri
-
依托单位:
Persistent microRNA changes in serum of cancer-free breast cancer patients
-
批准号:8240038
-
项目类别:
-
资助金额:$16.75万
-
财政年份:2011
-
负责人:Harikrishna Nakshatri
-
依托单位:
Persistent microRNA changes in serum of cancer-free breast cancer patients
-
批准号:8104694
-
项目类别:
-
资助金额:$20.1万
-
财政年份:2011
-
负责人:Harikrishna Nakshatri
-
依托单位:
Anthrax Toxin Receptor as a marker and target of breast cancer stem cells
-
批准号:8244440
-
项目类别:
-
资助金额:$16.75万
-
财政年份:2011
-
负责人:Harikrishna Nakshatri
-
依托单位:
Chemoprevention of tobacco carcinogen-induced bladder cancer
-
批准号:8009718
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2010
-
负责人:Harikrishna Nakshatri
-
依托单位:
Chemoprevention of tobacco carcinogen-induced bladder cancer
-
批准号:8136673
-
项目类别:
-
资助金额:$7.47万
-
财政年份:2010
-
负责人:Harikrishna Nakshatri
-
依托单位:
Lung Cancer Chemoprevention through LC-1
-
批准号:7686709
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2008
-
负责人:Harikrishna Nakshatri
-
依托单位:
Lung Cancer Chemoprevention through LC-1
-
批准号:7590720
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2008
-
负责人:Harikrishna Nakshatri
-
依托单位:
Animal Model for Local Inflammation-Induced Breast Cancer
-
批准号:7500316
-
项目类别:
-
资助金额:$7.58万
-
财政年份:2007
-
负责人:Harikrishna Nakshatri
-
依托单位:
Animal Model for Local Inflammation-Induced Breast Cancer
-
批准号:7388684
-
项目类别:
-
资助金额:$7.58万
-
财政年份:2007
-
负责人:Harikrishna Nakshatri
-
依托单位:
Chemoprevention Through Activation of Estrogen Receptor Alpha-Induced Senescence
-
批准号:7151278
-
项目类别:
-
资助金额:$7.58万
-
财政年份:2006
-
负责人:Harikrishna Nakshatri
-
依托单位:
Chemoprevention Through Activation of Estrogen Receptor Alpha-Induced Senescence
-
批准号:7259375
-
项目类别:
-
资助金额:$7.36万
-
财政年份:2006
-
负责人:Harikrishna Nakshatri
-
依托单位:
Cancer Biology Training Program
-
批准号:7599246
-
项目类别:
-
资助金额:$32.15万
-
财政年份:2005
-
负责人:Harikrishna Nakshatri
-
依托单位:
AKT MEDIATED TAMOXIFEN RESISTANCE IN BREAST CANCER CELLS
-
批准号:6514819
-
项目类别:
-
资助金额:$23.47万
-
财政年份:2001
-
负责人:Harikrishna Nakshatri
-
依托单位:
海外基金